Background. A randomized, controlled, long-term varicella vaccine efficacy study (NCT00226499) was conducted in several European countries with no universal varicella vaccination. The control group allows studying the immunological response profiles to natural varicella exposure and disease in children from 1 year of age onwards.
Background.
A randomized, controlled, long-term varicella vaccine efficacy study (NCT00226499) was conducted in several European countries with no universal varicella vaccination. The control group allows studying the immunological response profiles to natural varicella exposure and disease in children from 1 year of age onwards.
Methods. Of 5,803 subjects enrolled in the study, 744 were vaccinated with 2 doses of measles-mumps-rubella vaccine as active control. Follow-up lasted for up to 10 years. Varicella case ascertainment was done by combining PCR testing of skin lesions, epidemiological context and blinded clinical case adjudication by independent experts. A confirmed case required a positive PCR result or a positive epidemiological context with a positive case adjudication.
Results. In the control group, a total of 352 confirmed varicella episodes were captured; of which, 339 had an available serum sample taken before and after the episode at any of the year 1 or bi-yearly visits scheduled per protocol. All subjects were seronegative for anti-VZV antibodies before vaccination. The immunological profile showed that 96% of subjects with varicella episodes experienced an 8-fold increase of the anti-VZV titers when comparing the sample available after the episode vs. the one before the episode. The data indicate that the GMC levels were similar to that induced by 2-dose immunization with varicella vaccines, and persisted over many years after the varicella episode without indication of waning (figure). In subjects without any reported varicella episode, 8-fold increases of the anti-VZV titers between 2 successive blood samples were measured in up to 34% of consecutive pairs of serum samples.
Conclusion.
To our knowledge, this is the first long-term analysis of the immunological history of anti-varicella immunological profile in young children exposed to a high varicella force of infection. About one-third of subjects not vaccinated against varicella developed an anti-VZV immune response although no varicella disease was reported. Sub-clinical varicella may occur more frequently than anticipated. The total incidence of varicella infections might be under-estimated by syndromic surveys only.
Funding: GlaxoSmithKline Biologicals SA. Methods. Medical evaluation was performed on 38 babies with MCP, up to 17 months old, followed at a center for child rehabilitation in RN. All subjects underwent CT brain scan. Cohort enrollment occurred with subjects born between January 2015 and May 2016.
Results. 38 babies with MCP underwent head CT. 68.5% were male, 31.5% were female. The main clinical presentations were spasticity, irritability and seizure. On CT, all subjects had brain volume reduction. Intracranial calcification (IC) was observed in all of the subjects who presented with irritability and seizures (n = 27) and in 83.3% of subjects with spasticity. Lissencephaly was seen in 80% of subjects with irritability, 75% of subjects with seizures and 50% with spasticity. Ventricular dilatation was seen in 19 subjects, all of whom had spasticity, 60% who presented with irritability and 50% who presented with seizures.
Conclusion. These new data from a relatively large study, demonstrate that neuroradiographical findings are associated with clinical syndromes in affected neonates. IC was the most prevalent CT scan finding (after reduction in the brain volume). It seems to be the most common radiological finding related to neuro-clinical disorders in ZIKV infection. This study may be used to better describe the congenital Zika syndrome, its clinical/radiological outcomes and natural history.
Disclosures. All authors: No reported disclosures. This study aimed to evaluate CT scan findings in living babies whose mothers had exanthematous diseases (ED) compatible with ZIKV infection during their pregnancy.
Radiological Findings in Microcephaly Cases
Methods. We evaluated the CT brain scan images of 38 subjects up to 17 months whose mothers had ED during pregnancy. All these MCP cases were followed at a reference center for children rehabilitation in RN. Cohort enrollment occurred within babies born between January 2015 and May 2016.
Results. All subjects had brain volume reduction, followed by intracranial calcification (N = 27). Lissencephaly and ventricular dilatation were found in 19 cases. Pachygyria was observed in 11 subjects (28.9%) and cerebellar atrophy was observed in 8 subjects (21%). All subjects reported with pachygyria had lissencephaly. In addition, all subjects observed with intracranial calcifications had pachygyria.
Conclusion. It is a large and well detailed case series of CT brain scan performed in living babies with MCP related to ZIKV. These findings observed are supportive evidence to prove the severity of brain damages caused by ZIKV due to its neurotropism. This pattern of CT scan images should be compared with CT brain images observed Background. This is a multisite study of cases of acute flaccid myelitis (AFM) in Texas during the year 2016 among 6 children's hospitals. AFM is a newly recognized and poorly understood disease. Information related particularly to pathogenesis, treatment, and recovery are lacking.
Methods. Children age 0-18 years admitted with AFM defined as acute onset limb weakness with spinal cord lesions on MRI primarily involving gray matter during January 1-December 31, 2016, were reviewed. Abstracted information included demographics, presentation, laboratory findings, treatments, and long-term outcomes up to 18 months after onset of weakness (range 3.5-18 months; median 15 months).
Results. 22 patients from 5 hospitals were included. Median age was 4.9 years. Upper extremity involvement was common (77%), with all extremities being involved in 36%. Enterovirus D68 was identified in 3 cases. Other pathogens identified included human parechovirus (n = 2), human herpesvirus 6 (n = 1), non-D68 enterovirus (n = 2), rhinovirus (n = 1), Mycoplasma pneumoniae (n = 1), Bartonella henselae (n = 1), and influenza B (n = 1). In total, 32% recovered fully in strength and function, and 45% had full recovery of function. 18% remain completely dependent on caregivers. All extremities were involved in 8 patients. 6 had significant residual weakness, ranging from flaccidity in one extremity to complete caregiver dependence. One was lost to follow-up after discharge. None of the three patients with Enterovirus D-68 made a full recovery, and all three remain largely dependent on caregivers. Treatments varied, but most commonly included methylprednisolone (n = 14) or intravenous immunoglobulin (IVIG) (n = 13). All cases of full recovery were treated with steroids, IVIG, or both. 4 patients were not treated; 2 with eventual recovery of function (Figure 1 ). Response to IVIG and steroids was variable; no harm was noted in response to IVIG (Figure 2) .
Conclusion. Our findings overall show more promising outcomes than those seen in the 2014 nationwide outbreak of AFM. Specific treatments were not associated with better outcomes. IVIG appeared to be helpful in several cases and, at the very least, was not harmful. Patients with all extremities involved and/or enterovirus D68 appear to have poorer outcomes.
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Validation of a Novel Scoring Criteria for Assessing the Severity of Viral Respiratory Infections in Children
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Background. Novel investigative tools (e.g., whole-genome sequencing) help characterize host and viral genetic contributions to disease severity in pediatric viral respiratory infection. However, a validated scoring system for quantifying illness severity is needed to properly contextualize results. Existing scoring systems are outdated, unvalidated and underpowered. We thus developed a scoring system to address these concerns.
Methods. Children hospitalized with viral respiratory infections were prospectively enrolled over 2 years, with 51 clinical variables abstracted from the medical record. 7 variables felt to be most predictive of disease severity and significantly correlated with each other (Spearman correlation coefficient P < 0.001) were included in the scoring system (duration of hospital and ICU stay, oxygen and high flow nasal cannula (HFNC) use and intubation; maximum nasal cannula and HFNC support), and combined into a disease severity index by converting each into an ordinal score and summing over the variables, with each variable sub-divided into 7 levels of exposure (based on equal interval length cutpoints). For a validation comparison, sampling algorithms utilizing a linear model selected a subset of 96 patients whose disease severity would be randomly assessed by 8 pediatricians in blocks of 12, using D-optimality and space filling criteria to protect against non-linearity (severity scored 1 to 10; 80% power for detection of correlation >0.28, two-sided α = 0.05). Mixed model regression analyses compared clinician-scored disease severity with the scoring system. Akaike Information criteria (AIC) and coefficients of determination (R 2 ) ranked severity indices.
Results. 445 subjects (56.2% male, median age 1.2 years) were enrolled. Clinician scores of disease severity averaged 6.2 (SD = 2.2, range 1-10). A scoring system using 7 variables with 7 levels of exposure per variable produced the lowest AIC (0.00, R 2 = 0.70 for predicting clinician-scored disease severity after adjustment for rater effects) (Figure 1) .
Conclusion. A 7-variable scoring system quantifying disease severity in pediatric viral respiratory infections correlates well with clinician assessment, and may advance the study of such infections. Background. Children are commonly affected by skin and soft-tissue infections (SSTIs); however, data are limited on clindamycin as a preferred treatment and whether resistance testing is impactful. This study was done to determine whether empiric clindamycin use leads to a curative clinical outcome with respect to adverse effects and correlating D-Test resistance.
Clinical Outcomes of Clindamycin Use in Skin and
Methods. This retrospective chart review evaluated pediatric patients >18 years of age, who received clindamycin for a SSTI from January to July 2017. The following patient characteristics were collected: patient demographics (age, weight, admitting diagnosis, and past medical history), type of SSTI, need for incision and drainage, antimicrobial(s) administered, antimicrobial sensitivity profile, culture results, and D-Test results. The primary outcomes of the study were days to symptom resolution and overall length of stay (LOS) in the hospital. The secondary outcome was adverse effects of clindamycin and D-Test results.
Results. A total of 32 patients met the inclusion criteria with a mean age 6.9 ± 5.9 years. Twenty-four (75.0%) patients had cellulitis, seven (21.9%) had abscesses and one (3.1%) patient had both. Thirteen (40.6%) patients had methicillin-resistant Staphylococcus aureus (MRSA) isolated, while four (12.5%) had methicillin-sensitive Staphylococcus aureus (MSSA) isolated. The overall mean time to symptom resolution occurred at 1.7 ± 0.7 days with an average LOS of 2.3 ± 0.7 days. Four (12.5%) patients were clindamycin-resistant and 12 (37.5%) were erythromycin resistant. Seventeen patients (53.1%) had a D-Test done prior to clindamycin use and of those, five (15.6%) were D-Test positive. The mean time to symptom resolution (1.4 ± 0.9 vs. 1.7 ± 0.7 days)
